On symptoms, the Phase 2 showed a positive trend: dysphagia symptom scores improved more in the 360 mg cendakimab group than placebo, but the difference fell just short of statistical significance at 16 weeks ( p = 0.073) [ 89 ].
← all excerpts
The Therapeutic Pipeline for Eosinophilic Esophagitis: Current Landscape and Future Directions.
2
0.0730
0.0730
The sentences
The drug’s administration showed a trend toward improved dysphagia symptoms compared with placebo.